OSCR

ANALYST NOTE: OSCAR HEALTH, INC. (OSCR) DATE: 2026-06-13 CURRENT PRICE: $28.40

1. Structural Readiness

• Conservative Entry: Not yet defined (requires a confirmed breakout close above the consolidation high).
• Aggressive/Pre-Breakout Entry: Not actionable on setup alone; requires confirmation.
• Breakout Level: Not yet established (requires price to close above the current consolidation range).
• Current Price: $28.40.
• Extension: Not applicable (price is within the forming range, not extended above a breakout).
• ATR Context: Current ATR is 5.7% (High). This indicates elevated volatility, which is within the historical "sweet spot" (4–6%) for structural quality, suggesting the setup has sufficient momentum to move but requires careful position sizing.

2. Thesis Layer

• Thesis Classification: TACTICAL / SETUP-LED.
• Macro Thesis: There is no named secular thesis attached to this specific setup as of 2026-06-13.
• Judgment Framework: The conviction must be derived entirely from the quality of the structural setup (the forming coil) and the immediate business fundamentals (profitability trajectory, membership growth, and margin expansion). Do not invent a macro narrative; judge the name on its ability to execute the "Margin Inflector" archetype based on the evidence provided.

3. Business Overview

Oscar Health, Inc. operates as a health insurance provider and technology platform across the United States.

• Core Business: The company offers health plans through the Patient Protection and Affordable Care Act (ACA) serving individuals, families, and employees. As of March 31, 2026, the company serves approximately 3.2 million effectuated members, representing a 56% year-over-year increase (Evidence E6, E10, E12).
• Market Position: Oscar is the largest carrier fully dedicated to the individual market (Evidence E5). It serves a fundamental pillar of American healthcare, targeting entrepreneurs, gig workers, and early retirees (Evidence E7, E8).
• Technology & Diversification: Through its "+Oscar" platform, the company provides health technology solutions, including the "Campaign Builder" platform which serves nearly 0.6 million client lives (Evidence E9, E17). The company has expanded its offerings to 20 states for 2026 (Evidence E18).
• Financial Performance (Q1 2026):
• Revenue: Premium revenue increased 53% year-over-year to drive toward a full-year guidance of $18.7 billion to $19.0 billion (Evidence E2, E11).
• Margins: The Medical Loss Ratio (MLR) is disciplined, expected to remain between 82.4% and 83.4% for the full year, with the lowest MLR in Q1 and highest in Q4 (Evidence E3, E13).
• Profitability: Management reaffirmed guidance for Earnings from Operations (EFO) of $250 million to $450 million for 2026, signaling a shift to meaningful profitability (Evidence E1, E4).
• Capital Structure: Combined statutory capital and surplus was estimated at $1.7 billion as of March 31, 2026, well in excess of minimum requirements (Evidence E14).

4. Archetype and Conviction

• Archetype: Margin Inflector.
• *Fit:* The company is transitioning from a growth-at-all-costs model to a profitable operator. The evidence shows a disciplined pricing strategy, favorable prior period reserve development, and a clear path to positive Earnings from Operations ($250M–$450M) while maintaining high membership growth (56% YoY). The MLR compression (decreasing in Q1 2026 vs 2025) directly supports the "inflector" narrative.
• Valuation Context: The financial spine indicates a forward consensus EPS of $0.9011 (FY1) and $1.33472 (FY2) (Evidence E26). This implies the market is pricing in significant earnings expansion as the company scales.
• Conviction Stack:
• *Thesis Strength:* Moderate (Tactical, no macro tailwind named).
• *Evidence Quality:* High (Strong earnings guidance, clear membership growth, disciplined MLR).
• *Structural Quality:* Moderate (ATR of 5.7% is healthy; setup is "Forming" rather than "Confirmed").
• *Setup Readiness:* Partial. The coil is forming, meaning the structure is valid, but the breakout has not fired.
• *Rerating Potential:* High, contingent on the successful execution of the 2026 profitability guidance and the continuation of the 56% membership growth trend.

5. Invalidations, Strengths, and Gaps

• What Would Strengthen the Case:
• A confirmed close above the current consolidation range (breakout) with volume.
• Management reiterating or raising the 2026 EFO guidance range ($250M–$450M) in subsequent calls.
• Continued MLR compression below the 82.4% floor.
• What Would Invalidate the Case:
• A significant deviation from the $18.7B–$19.0B revenue guidance or a widening MLR beyond 83.4%.
• A slowdown in membership growth below the 56% YoY trajectory.
• Gaps in Evidence:
• Specific Breakout Level: The exact price level for the breakout (the top of the consolidation range) is not provided in the evidence block, preventing a precise entry definition.
• Competitive Landscape: No specific data on competitor MLR or market share shifts in 2026 is provided.

PRIVATE ANALYST CALL

Judgment: Speculative Confidence: medium Key evidence: 1) Management reaffirmed full-year guidance for $250M-$450M Earnings from Operations in 2026. 2) Membership grew 56% YoY to 3.2 million members as of Q1 2026. 3) MLR decreased in Q1 2026 due to disciplined pricing and favorable reserve development. 4) Forward consensus EPS projects growth from $0.90 to $1.33 over FY1-FY2. Key risks: 1) Setup is currently "Forming" with no confirmed breakout, limiting immediate structural conviction. 2) Elevated ATR of 5.7% suggests high volatility and potential for whipsaw. 3) Reliance on ACA market dynamics and potential regulatory shifts. 4) No named secular thesis to provide macro tailwinds. Sizing hint: Position size should be conservative given the "Forming" state; treat as a partial setup readiness signal rather than a confirmed entry. Expected path: Management expects to deliver meaningful profitability in 2026 with revenues between $18.7B and $19.0B; the stock likely needs to clear the consolidation range to confirm the margin inflector thesis. Expected horizon: 3 to 6 months for the setup to resolve into a confirmed breakout or invalidation.